prep bottom cost posit
recoveri captur share
lt healthi work manag s-t choppi
face outbreak mass market uncertainti deliv
better vs expect equip growth better cost manag
trajectori alway go wide rang potenti outcom
declin seen april fall ballpark
earlier week take step need order best posit
manag current downturn come side better
on-going cost cut strong new product portfolio market effort like one ds
see well posit near term could quit soft still see healthi
long-term pathway therefor reiter buy rate po
expect on-going headwind recoveri slow
lower ep ep
estim reduct mostli driven lower revenu estim given
pace potenti recoveri although expect tri balanc cost
opportun revenu shortfal biggest chang estim
reduct lesser reduct
track expect outbreak impact
busi beyond key short-term growth rate includ updat
around equip consum purchas trend well rate
dental offic reopen overal biggest focu next month
remain combin quickli patient volum normal impact
outbreak longer term dental equip spend final could hear
increment updat one ds roll-out uplift could provid
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
pandem
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one world largest dental
manufactur provid dental offic total
solut rang consum high-end
equip compani headquart york
pennsylvania oper
believ well-posit capit
equip refresh follow launch
primescan digit impress tool addit
see clear pathway sustain ep
growth multi-year cost save
outlook well see favor risk/reward
track line expect first two month declin
significantli march
adj oper marginlow volum higher cost
technolog equip revenu grew driven strong
sale primescan/primemil
us declin y/i experienc growth technolog equip off-set
declin organ sale consum
 grew consum declin row region
gross margin driven lower level sale
expect capital-expenditure lower year previous
unlik spend
see volum april far us emea slowdown
start mid-march
fall-off patient traffic across eu april
china see slow growth track lot better januari
expect restor endodont first procedur return
implant ortho like come back slowli
color margin start think
difficult provid guidanc next quarter
number came expect abl take action
data china look like april vs januari lead indic
offic open faster patient traffic return
think capital-expenditure dental offic reopen updat
relationship dso
digit offic improv product go remain
import offic expect help equip grow
volum declin global comment
process went risk-weight quarter
think valu one backdrop
conclud base sensit analysi prudent adjust carri
valu unit
specif equip
sale feel good level awar one see
restart
one help peopl start
comparison realist thing recov year
sirona grow rapidli
didnt see real drop equip far
peopl use health benefit recessionari environ healthcar
tend lag
recov bit slower peopl need get back work get
consum vs technolog trend quarter
quarter number good
lag effect goe retail wholesal
manag
see capital-expenditure place disrupt
sens long could take/how gradual return could
possibl could extend next year
start see move back elect global
think buyback
short term higher prioriti cash conserv import
want preserv cash invest thing matter remain
competit come cycl
cost variabl natur go cycl
fix cost becom variabl
endo busi hold
endo mostli emerg relat hold okay
sale account cycl equip account revenu
go chang
deferr sale point think chang
reboot equip asia
korea hong kong taiwan seem littl front
busi perform line one anoth
equip held fairli well
japan never realli shut dental offic slow demand
consum equip perform similarli implant slow
price object base ebitda estim
mani direct pure-play competitor compar multipl
low-double-digit estim think trade premium given
compani pure manufactur meaning margin expans potenti
would note multipl five year averag balanc
downsid risk slowdown total demand tie outbreak lag
equip sale either failur reignit growth continu distribut channel
challeng well continu slowdown consum market inabl
achiev compani margin target upsid risk po better-than-
expect equip sale success sale forc market effort
launch primescan well strong consum sale driven faster rebound
consum market heavi invest margin expans cost save
benefit drove overachiev initi save target
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
